–ѕа°±б>ю€ ю€€€ю€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ l …бЅњјв\pThe Free Software Foundation BдЬ=PF0*8X@Н"ЈЏ1іР Helvetica1іРCourier1іР Courier New1іЉ Courier New1іР Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)ах€ ј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј ах€ фј а ј а+х€ шј а)х€ шј а,х€ шј а*х€ шј а х€ шј а –И ~~ња ЎИ ~~ња#ЎИ ~~ња ЎИ ~~ња8#№И ~~њУА€УА€УА€УА€УА€УА€Тв8€€€€€€€€€€€€АААААААААјјјАААЩЩ€Щ3f€€ћћ€€ff€ААfћћћ€А€€€€€€ААААА€ћ€ћ€€ћ€ћ€€ЩЩћ€€ЩћћЩ€€ћЩ3f€3ћћЩћ€ћ€Щ€fffЩЦЦЦ3f3Щf333Щ3Щ3f33Щ«««Е"NOTIFICATION OF LATE FILINGЕ$ўPART I REGISTRANT INFORMATIONЕ BPART IV OTHER INFORMATION l …   dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?дPART I REGISTRANT INFORMATIONPART IV OTHER INFORMATIONU } <} $ } 0} $ }   ббббббббб б б б б бббббббббббARGOS THERAPEUTICS INCNT 10-Q 11/14/2018#NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D    o Form N-SAR  o Form N-CSR             For Period Ended: September 30, 2018  (  o Transition Report on Form 10-K    (  o Transition Report on Form 20-F  ( o Transition Report on Form 11-K( o Transition Report on Form 10-Q)!o Transition Report on Form N-SAR( For the Transition Period Ended:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/„4Rћё€Ћ€µ€©€В€v€j€^€«ю[ююіэXэьь†ьDьзыЧы7ы+ыычъ=PF0*8X> ґ@еb      l … Ќ  dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?дNOTIFICATION OF LATE FILINGPART IV OTHER INFORMATIONU } √1 ббббббббб б б б б ббббббббббббARGOS THERAPEUTICS INCNT 10-Q 11/14/2018'PART I - REGISTRANT INFORMATION Argos Therapeutics, Inc. Full Name of Registrant  ! Former Name if Applicable 4233 Technology Drive-%Address of Principal Executive Office(Street and Number)$Durham, North Carolina 27704 City, State and Zip Code$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/„6Ьаё€Ћ€µ€©€~€r€f€Z€6€€€ыю÷ю ю©юxюYюMю%ююхэйэЅэ=PF0*8X> ґ@ l … [∆!,Р4  dь©с“MbP?_*+ВА%€БјМ,БЅГД&¬ў≠e2ў?'¬ў≠e2ў?(¬ў≠e2ў?)¬ў≠e2ў?°",D/а?а?дNOTIFICATION OF LATE FILINGPART I REGISTRANT INFORMATIONU } U} <} $ }  } $ } a [ббббббббб б б б б бббббббббббббббббббARGOS THERAPEUTICS INCNT 10-Q 11/14/2018#PART IV - OTHER INFORMATION~ ю€€€6.Name and telephone number of person to contact & in regard to this notification   Richard Katz ~ ¶с€€  287-6315  (Name)   (Area Code)  (Telephone Number)  ~ ъ€€€0 (Have all other periodic reports required3+under Section 13 or 15(d) of the Securities1)Exchange Act of 1934 or Section 30 of the1)Investment Company Act of 1940 during the/'preceding 12 months or for such shorter/'period that the registrant was required4,to file such report(s) been filed? If answer"is no, identify report(s). x Yes o No~ ц€€€.&Is it anticipated that any significant0(change in results of operations from the0(corresponding period for the last fiscal91year will be reflected by the earnings statements7/to be included in the subject report or portionthereof?„D–lё€Ћ€µ€©€В€v€j€^€€аюВюю€эљэzэ9эшьєьzь6ььмыШыАы8ышъЄъxъ/ъищ б!б"б#б$б%б&б'б(б)б*б+б,б-б.б/б0б1б2б3б4б5б6б7б8б9б:б;б<б=б>б?б       x Yes o No!!!!!!"7"/If so, attach an explanation of the anticipated#4#,change, both narratively and quantitatively,$.$&and, if appropriate, state the reasons%0%(why a reasonable estimate of the results&&cannot be made.''(1()In April 2018, the Company terminated its)0)(development program for rocapuldencel-T,*6*.which it had been developing for the treatment+.+&of metastatic renal cell carcinoma and,1,)other cancers. As a result, the Company?s---%research and development expenses for.1.)the three and nine months ended September/1/)30, 2018 are expected to be less than for0800the same periods in 2017. Due to the exploration1-1%of a strategic alternative, including2/2'an asset sale, dissolution, liquidation303(or protection under bankruptcy laws, the424*Company is not able to provide an estimate5.5&of results of operations at this time.667"7Forward-looking statements88919)Except for statements of historical fact,:1:)the matters discussed in this Form 12b-25;/;'are ?forward-looking statements? within<0<(the meaning of the applicable securities=4=,laws and regulations. The words ?estimates?,>->%?expects? and similar expressions are?,?$intended to identify forward-looking„D lђ€d€€ўюЫю[ю4ююџэЫэUээ÷ьЩьXььѕыТыSыы—ъУъ{ъIъ1ърщѓщpщ0щмш@бAбBбCбDбEбFбGбHбIбJбKбLбMбNбOбPбQбRбSбTбUбVбWбXбYбZб@4@,statements, although not all forward-lookingA,A$statements contain these identifyingB4B,words. Forward-looking statements, includingC4C,statements regarding the Company?s estimatesD2D*of its operating results for the three andE5E-nine months ended September 30, 2018, involveF.F&risks and uncertainties that may causeG0G(actual results to differ materially fromH3H+those stated here. Factors that could causeI0I(actual results to differ materially fromJ/J'those in the forward-looking statementsK1K)include, but are not limited to, the riskL-L%that additional information may ariseM0M(from the completion of the review of theN0N(Company?s results of operations, as wellO2O*as other risks described more fully in theP7P/Company?s filings with the SEC. Forward-lookingQ0Q(statements reflect management?s analysisR3R+as of the date hereof. The Company does notS/S'undertake to revise these statements toT(T reflect subsequent developments.UUVW$X____________________________1Y)Created by Morningstar Document Research.0Z(http://documentresearch.morningstar.com/„:-Љ€А€<€шюґюqю3юуэ∞эpэ1эрь≥ьsь3ьсы™ыjы'ыиъ∞ъШъМъАъXъ=PF0*8X> ґ@еCZZYYXXTTSSRRQQPPOONNMMLLKKJJIIHHGGFFEEDDCCBBAA@@??>>==<<;;::9977554433221100//..--,,++**))((&&%%$$##""   Root Entry€€€€€€€€ јFю€€€Book €€€€€€€€€€€€ '7 ю€€€ю€€€э€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€